August 4, 2022 – The American Medical Association (AMA) announced an update to Current Procedural Terminology (CPT)®, the nation’s leading medical terminology code set for describing health care procedures and services, that includes a new laboratory test code for the orthopoxvirus and two codes for the vaccines being utilized to prevent monkeypox infection.
These new CPT codes are effective for immediate use and are designed to clinically distinguish the diagnostic test and vaccinations for monkeypox to support data-driven tracking, reporting and analysis necessary for resource planning and allocation during the public health response to the outbreak, the AMA said in a release .
“In the wake of the World Health Organization (W.H.O.) declaring monkeypox a global health emergency, and with case numbers increasing in the United States, these CPT updates are timely,” said AMA President Jack Resneck Jr., M.D. “The daily increase in cases in the U.S. shows community spread occurring; however we are relieved to see access to testing has increased to 80,000 specimens per week with commercial labs now online and vaccine supply is increasing. Monkeypox is most often spread person to person through close personal contact, but preventive measures can help you avoid infection. We urge patients to check trusted, evidence-based sources like the CDC and AMA and to contact their physician if they have questions about prevention, diagnosis, or treatment of monkeypox.”
The new laboratory test CPT code (87593) describes molecular diagnostic testing that detects the nucleic signature of an orthopoxvirus, including the monkeypox virus.
The two new vaccine codes are designed to describe the two smallpox and monkeypox virus products currently available.
The first code (90622) describes the existing FDA-approved ACAM2000 vaccine manufactured by Sanofi Pastuer Biologics Co. for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection.
The second code (90611) describes the FDA-approved JYNNEOS vaccine manufactured by Bavarian Nordic for prevention of smallpox and monkeypox disease in adults 18 years of age and older at high risk for smallpox or monkeypox infection.